Itamar Medical: New fee schedule advances WatchPAT
By HME News Staff
Updated Fri November 16, 2018
CAESAREA, Israel - The recently released 2019 fee schedule from CMS should support broad use of Itamar Medical's WatchPAT technology, the company says. WatchPAT uses peripheral arterial tone (PAT) technology to provide cardiologists and sleep physicians in the United States with accurate sleep diagnoses. “We believe that the new CMS fee schedule validates the clinical value of our sleep tests for patients and may significantly advance utilization of our sleep tests in the U.S. market,” said Gilad Glick, CEO of Itamar Medical. “It also reflects growing awareness of deploying home sleep apnea testing and sleep apnea management as essential components of the cardiology care pathway.” Itamar Medical estimates that WatchPAT technology accounted for about 15% of the home sleep tests in the U.S. in 2017.
Comments